Human medicines European public assessment report (EPAR): Andembry, garadacimab, Date of authorisation: 10/02/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Fymskina, ustekinumab, Date of authorisation: 25/09/2024, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Sprycel, dasatinib (anhydrous), Date of authorisation: 20/11/2006, Revision: 48, Status: Authorised

Procedural timetables

Committee for Herbal Medicinal Products (HMPC): 6-8 July 2026, European Medicines Agency, Amsterdam, the Netherlands, from 6 July 2026 to 8 July 2026

Minutes of the HMPC meeting 6-8 July 2026

List of centrally authorised products with safety-related changes to the product information

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28 September - 1 October

Human medicines European public assessment report (EPAR): Itvisma, onasemnogene abeparvovec, Date of authorisation: 30/06/2026, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Bysumlog, insulin lispro, Date of authorisation: 06/05/2026, Revision: 2, Status: Authorised